PubMed Health⌕ Search

Biomedical subjects

M Mydlik

Publications and source records attributed to M Mydlik.

5 recordsLinked to original sources
PubMed1999

[Vitamin levels in the serum and erythrocytes during erythropoietin therapy in hemodialyzed patients].

BACKGROUND: The treatment of anaemia by erythropoietin is the method of choice in chronic renal failure patients without dialysis treatment, in hemodialyzed patients and during CAPD. Erythropoietin treatment influenced supplementary doses of vitamins especially those participating in haem formation. OBJECTIVES: The aim of the study was to investigate the influence of erythropoietin treatment during long-term 15 months study on serum vitamin A levels and its protein carriers, prealbumin and retinol-binding protein, on erythrocyte vitamin B1, B2 and B6 and folic acid and on serum or plasma vitamins B12, C and E levels in hemodialyzed patients. METHODS: The authors investigated the influence of erythropoietin on the biochemical parameters mentioned above in 30 hemodialyzed patients during the period of 15 months. Patients were divided into two groups. Group A was formed by patients without erythropoietin treatment and group B was treated by subcutaneous administration of erythropoietin. Total weekly dose of erythropoietin was 50-100 U/kg of body weight. All patients received perorally pyridoxine 5 mg/day. B group of patients was supplemented by pyridoxine 20 mg/day and by folic acid 10 mg/day from the 12th to 15th month of the study. Erythrocyte vitamins B1, B2 and B6 values were determined by indirect enzymatic methods and were expressed as the effects of their coenzymes, thiamine pyrophosphate, flavine adenine dinucleotide and pyridoxal-5-phosphate in per cents. RESULTS: Long-term erythropoietin treatment led in the 12th month to a significant decrease of serum vitamin A and its protein carriers which were significantly increased in both groups of patients during the whole study. Erythrocyte vitamin B6 and folic acid significantly decreased due to erythropoietin treatment. Supplementary doses of pyridoxine and folic acid given perorally to the patients in B group during the last three months of our study influenced the deficiency of erythrocyte vitamin B6 and folic acid. CONCLUSIONS: Supplementations of pyridoxine in the dose of 20 mg/day and of folic acid 5 mg/week in hemodialyzed patients during erythropoietin treatment are necessary. (Tab. 5, Ref. 28.)

Anemia↗
PubMed1993

Erythrocyte vitamins B1, B2 and B6 and erythropoietin.

The influence of recombinant human erythropoietin (r-HuEPO) on erythrocyte vitamins B1, B2 and B6 was investigated in regular dialysis treatment (RDT) patients during a long-term 9-month study. Twenty-six RDT patients were divided into two groups. Group A was without r-HuEPO treatment while group B was treated by subcutaneous injection of r-HuEPO. The total maintenance weekly dose of r-HuEPO was 50-100 U/kg. Group A of patients was supplemented with oral pyridoxine 5 mg/day during the period of 9 months; group B was supplemented with oral pyridoxine 5 mg/day for the first 6 months and with 20 mg/day during the following 3 months. At the end of the study, significant increase in erythrocyte vitamin B2 and significant decrease in erythrocyte vitamin B6 were found. Supplementation with 20 mg/day of pyridoxine led to a significant increase in vitamin B6 and at the end of the 9 months, the values of vitamin B6 were within the normal range. These results provide indirect evidence that erythrocyte vitamin B6 is consumed by the hemoglobin synthesis during r-HuEPO treatment in RDT patients.

Anemia↗
PubMed1992

Erythrocyte vitamin B1, B2 and B6 in nephrotic syndrome.

Vitamin status was evaluated in 33 patients with chronic glomerulonephritis and nephrotic syndrome who had normal glomerular filtration rates. Erythrocyte vitamin B1 and B2 were within the normal reference range. Vitamin B6 was significantly decreased. Long-term, 6-month supplementation with riboflavin, 2 mg/24 h, and pyridoxine HCl, 50 mg/24 h, in 9 patients improved erythrocyte vitamin B2 and B6 levels even though the clinical status and the disease activity of the basic disease persisted or progressed.

Erythrocytes↗